valu usd unless otherwis note
shelter high-qual upgrad outperform
view upgrad sector perform outperform
believ high-qual defens portfolio recur
revenu outperform econom downturn danah
busi includ cepheid idtboth frontlin
close posit catalyst also big fan
danah water qualiti platform revenu
move higher qualiti curv defens safe
leverag recur revenu test-kit demand
global economi precipic spiral recess
believ investor move qualiti curv toward defens
safe haven weather loom macro headwind
recur revenu mix portfolio attribut healthcar
vertic consist rank among elit highest-qu
prime proprietari invest framework thank top-tier
organ growth free cash flow convers franchis strength
long view break glass case emerg
invest portfolio well-posit outperform
econom downturn financi crisi
industri recess importantli danah cepheid
busi combin revenu receiv us regulatori
approv test-kit product detect coronaviru
ramp product meet soar demand final
receiv us ftc approv pend bil acquisit
ge biopharma track close
backdrop upgrad sector perform outperform
rais price target impli upsid
potenti pushback mind share
outperform sector past three week elev
rel price-to-earnings valuat histor high end primari
motiv upgrad capit preserv bottom-fish
concern may fallout multi-industri
sector yet see neg econom datapoint
recessionari cascad pandem extent downturn
calibr feel confid recommend safe
rel valuat histor high danah rel price-to-earnings ep
premium multi-industri peer notion elev today
frankli less confid near-term earn trajectori
sector clear unchart territori histor
rang may prescript guidepost valuat trend
medium term price target assum danah
trade price-to-earnings ep premium peer
refer high end roper histor rel rang also
dissemin produc price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
given loom econom downturn market rotat
toward higher-qu defens safe haven believ
valuat expand roughli
price-to-earnings ep impli compani trade
roughli premium multi-industri peer thank
defens high-qual statu resili recur revenu
ep estim deriv price
target support outperform rate
market enter risk-off environ danah
deliv upsid synergies/accret target
believ stock may abl re-rat beyond high
end rel rang premium large-cap
peer ep also see potenti upsid
ep reach level includ acceler
organ growth end market improv would
carri execut risk misstep
 integr could weigh stock addit
high-qual defens name would lag
market enter prolong risk-on environ favor
cyclic higher-beta stock could see price-to-earnings contract
premium peer also risk
end market slowdown result ep closer
valuat
defens safe leverag recur revenu
test-kit demand global economi
precipic spiral recess believ
investor move qualiti curv toward
defens safe haven weather loom
macro headwind recur revenu mix
portfolio attribut healthcar vertic
long view break glass case
emerg invest portfolio well-
posit outperform econom downturn
financi crisi
industri recess importantli danah cepheid
busi combin revenu receiv us
regulatori approv test-kit product detect
coronaviru ramp product meet
soar demand
best-in-class multi-industri name metric
hold much-covet posit among higher-
qualiti prime coverag accord
sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
acquir biopharma busi bil
announc acquir biopharma
busi bil impli reason deal multipl
ev/ebitda deal expect produc
mil cost save roughli
cash ep accret ge biopharma lead provid
instrument consum softwar support
research discoveri process develop manufactur
workflow biopharmaceut drug
given expens price-tag below-benchmark
expect return major integr stumbl ge
biopharma pall cepheid would damag faith
investor disciplin
upgrad outperform
highli volatil recessionari environ global economi
precipic spiral recess due coronaviru pandem
sever fall-off oil price believ investor migrat qualiti curv
toward defens safe haven weather loom macro headwind
recur revenu mix portfolio attribut healthcare-ori end market
across life scienc diagnost vertic consist rank among elit
highest-qu prime proprietari invest framework thank top-tier organ
revenu growth free cash flow convers franchis strength view danah
well-posit manag econom downturn
financi crisi industri recess backdrop
upgrad danah sector perform outperform
danah portfolio outperform sector prior econom downturn
shown exhibit previou medic technolog segment
compris leica biosystem radiomet now-divest dental busi
abl significantli outperform sector averag period segment
oper profit actual increas y/i thank aggress cost-out restructur
initi believ segment best proxi danah portfolio
would perform today given compani exit major busi
segment time profession instrument industri technolog
tool compon mostli spin similarli
industri recess organ revenu continu deliv stabl
posit growth even rest sector succumb declin larg
attribut fact essenti zero oil ga heavi industri
exposur vertic heavili impact last oil price
collaps data-point support posit oper result
outperform broader sector loom econom downturn
danah medic vs sector recess danah organ growth vs sector industri recess
profitdanah medic technologiesmulti-industri sector organ growthshad area multi-industri sector averagenot restatedfor spin electr equip multi-industri
recur revenu compris mix driven razorblad consum
aftermarket servic project oper resili macro downturn
larg attribut sizeabl recur revenu mix expand
five year ago recur revenu driven extens instal base
instrument produc steadi stream high-valu mission-crit consum
aftermarket servic portfolio broadli follow razor/razorblad model
consum sale repres initi instrument sale also
instanc consum spece specif user applic due either
regulatori requir custom valid result custom sticki larg
captiv instal base final improv servic attach rate
deliv mid- high-single-digit servic revenu growth past three year result
one resili portfolio multi-industri sector view
cepheid ramp test product
cepheid receiv fda approv new rapid molecular test detect
danah cepheid busi announc receiv emerg use
author eua us fda xpert xpress rapid molecular
diagnost test detect coronaviru approxim minut
test design oper across cepheid global instal base autom
genexpert system begin ship custom week cepheid test-
kit leverag businesss flu detect pcr technolog one mani system
develop privat sector assist combat coronaviru pandem
strain global healthcar resourc earli size revenu contribut
test-kit note cepheid grown compound-annual-growth-rate sinc acquisit
contribut billion total revenu mix
diagnost mix expect cepheid revenu growth acceler demand
test-kit outstrip product capac medium term
expand
recur revenu
roughli mix
five year ago roughli
much portfolio follow
consum sale
repres
diagnost test detect
coronaviru
ramp product key compon use test patient sampl
danah integr dna technolog busi announc
ramp large-scal product key compon use test detect
coronaviru specif compon primer probe kit assist
dna analysi patient sampl thank cdc emerg use
author eua protocol ship enough compon enabl million
test conduct start week expect ramp manufactur
capac roughli million primer probe kit per week note first
us compani compon approv cdc use test-kit
earli size revenu contribut compon demand note
achiev double-digit growth sinc acquisit impli contribut
roughli million revenu mix life scienc mix
ge biopharma acquisit track close prior estim year-
cash ep accret announc receiv us ftc approv
billion acquisit biopharma busi effect secur necessari
regulatori clearanc transact deal track close consist
model assumpt manag target complet date recal
danah earn compani boost estim deal cash
ep accret includ annual interest cost million
blend interest rate less along dilut sale small life
scienc busi sartoriu ag roughli million help obtain anti-trust regulatori
approv said given recent fed rate cut respons econom
disrupt could see reduct ge biopharma deal financ cost
may produc upsid accret estim may partli off-set headwind
slower demand environ economi falter recess expect
manag provid color put take danah earn
mid-april bottom line success on-tim complet deal
provid major earn lift expect manag immedi
get work unlock million cost synergi
detail ge
pleas see
report
see potenti
upsid danah
accret target due
ge biopharma leader bioprocess workflow expect grow organ
low-doubl digit follow close acquisit
manag stand-alone oper compani within life scienc segment
rebrand cytiva busi lead provid instrument softwar
consum support research process develop manufactur
discoveri workflow biopharmaceut drug deliv mid-teen organ revenu
growth roughli ebitda margin annual free cash flow roughli
billion look ahead manag expect ge biopharma organ revenu growth
deceler low-doubl digit driven secular driver across biolog drug
develop cell gene therapi demand high growth market key
product line within busi includ downstream bioprocess revenu
mix upstream bioprocess
horizon
believ could eventu pursu spin-out water qualiti follow
complet acquisit stabil global market believ
begin orchestr separ best-in-class qualiti platform
total revenu either stand-alone busi pair product id
billion revenu water qualiti portfolio compris market-lead water test
analyt brand hach segment mix chemic disinfect brand chemtreat
ultraviolet disinfect brand trojan filtrat brand pall see
qualiti leagu within global water sector recur
revenu mix company-averag profit solid mid-single-digit organ growth
runway market share gain db implement commerci execut
new product innov busi sit squar high end water technolog
continuum command higher valuat barrier entri margin growth given
scarciti invest water pure-play market today believ publicli
trade qualiti would tremend appeal investor detail pleas
see recap qualiti analyst meet
danah rel price-to-earnings expand new record high past month
multi-industri sector sold-off dramat recent week share
rel resili past three week vs sector
result rel forward price-to-earnings ep premium multi-industri peer
expand notion elev today shown exhibit clear
unchart territori histor rang longer prescript guidepost
compani valuat trend medium term believ valuat
expand roughli price-to-earnings ep impli compani
trade roughli premium multi-industri large-cap averag today
driven defens high-qual statu resili recur revenu
ep estim deriv price target support outperform rate
clear
unchart territori
histor rel
rang longer
prescript guidepost
compani valuat
trend
refer high-
end roper histor
also
exhibit danah rel forward price-to-earnings premium multi-industri sector peer
note dhr price-to-earnings multipl ep
ev/ebitda premium ev/ebitda basi trade
estim repres rel premium multi-industri sector averag
surpris premium group given premium price-to-earnings
share price trade premium weight averag price-to-earnings
publicli trade peer cash ep believ deserv
premium reflect market leadership db toolkit
price assum after-tax cost capit beta annual sale growth
termin growth rate
new target assumesthat share trade premum sector exhibit danah quarterli incom statement
compani report capit market estim
millionsmarjunsepdecmarjunsepdecmarjunsepdecmarjunsepdecseg revenueslif dentalenvironment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens incomerest dental discontinu oper exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener incomelif appli expens oper income/expense- net interest intang per share earn per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper restat dental discontin oper electr equip multi-industri
given loom econom downturn market rotat toward higher-qu defens
safe haven believ valuat expand price-to-earnings
ep impli compani trade roughli premium multi-industri large-
cap peer thank defens high-qual statu resili recur revenu
ep estim deriv price target support outperform rate
risk rate price target
acquisit one acquisit compani sector alway risk
overpay experienc integr difficulti major deal believ
integr stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
three segment life scienc diagnost environment appli solut
also oper differenti framework growth lean leadership tool process
known danah busi system across aspect oper includ product
develop qualiti control global sourc sale market
modestli headquart washington employ peopl global
